Voltron Therapeutics
Voltron Therapeutics is dedicated to advancing immunotherapy through its revolutionary platform that precisely targets tumors and pathogens, engaging multiple components of the immune system to identify, target, and kill specific diseases. Founded in 2017, it holds an exclusive worldwide license to its technology, which has shown promising results in pre-clinical studies for infectious diseases and oncology. The company's mission is to deliver novel, highly efficacious treatments for cancers and infectious diseases, aiming to improve patient outcomes with faster, safer, and more flexible solutions.
Industries
Nr. of Employees
small (1-50)
Products
Modular self-assembling vaccine platform
A modular prophylactic and therapeutic vaccine platform that pairs a consistent immune-activating protein backbone with interchangeable antigenic attachments to generate targeted cellular immunity for oncology and infectious disease indications.
Modular self-assembling vaccine platform
A modular prophylactic and therapeutic vaccine platform that pairs a consistent immune-activating protein backbone with interchangeable antigenic attachments to generate targeted cellular immunity for oncology and infectious disease indications.
Services
Research partnerships and sponsored research agreements with academic centers to design and execute preclinical immuno-oncology and infectious disease studies.
Formation of joint ventures and licensing arrangements to co-develop platform applications and specific vaccine candidates.
Research partnerships and sponsored research agreements with academic centers to design and execute preclinical immuno-oncology and infectious disease studies.
Formation of joint ventures and licensing arrangements to co-develop platform applications and specific vaccine candidates.
Expertise Areas
- Vaccine platform development
- Immuno-oncology preclinical development
- Preclinical immunogenicity and efficacy testing
- Biologics CMC and scale-up
Key Technologies
- Self-assembling modular vaccine architecture
- HSP70-based protein immune adjuvant backbone
- Biotin–avidin style modular conjugation
- CHO cell line biologics production
News & Updates
The award will advance the development of the Self-Assembling Vaccine Platform for rapid production of vaccines for infectious diseases.
Initiating a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA).
The company announced significant immune responses in a dose-dependent manner in preclinical studies.
The award will advance the development of the Self-Assembling Vaccine Platform for rapid production of vaccines for infectious diseases.
Initiating a pre-clinical immuno-oncology trial targeting prostate stem cell antigen (PSCA).
The company announced significant immune responses in a dose-dependent manner in preclinical studies.